05.22 2025

[BioWorld] AP402 Clinical Trial Featured by Global News Outlet BioWorld

Exclusive interview with Dr. Jeng Her, CEO of AP Biosciences. AP402, targeting HER2-resistant tumors, is currently undergoing Phase I/II clinical trials in Australia.

04.30 2025

[Media Feature] AP402 Clinical Trial Featured by U.S. Patient Platform WhatNext

AP402, was recently featured in WhatNext, a trusted U.S.-based platform focused on cancer patient education and clinical trial awareness

04.29 2025

AP Biosciences Presents AP402 Preclinical Data at AACR

AP Biosciences Presents Preclinical Data on p95HER/CD137 T-Cell Engager at American Association of Cancer Research Annual Meeting

04.22 2025

FPD in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients

AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients

04.22 2025

AP Biosciences to Present New Preclinical Data at 2025 AACR Annual Meeting

Present new preclinical data for AP402, at the 2025 AACR Annual Meeting

03.07 2025

AP Biosciences to Sponsor Academic Talk at TSITC 2025 Annual Meeting

AP Biosciences is pleased to announce its participation in the 2025 Taiwan Society of Immunotherapy for Cancer (TSITC) Annual Meeting on March 15 at the Chang Yung-Fa Foundation Building in Taipei.

02.19 2025

AP Biosciences Invited to JP Morgan Healthcare Conference Taipei 2025

02.14 2025

Antibody 2.0: The Next Era of Innovation in Biologics

Jeng Her, CEO of AP Biosciences, shared his outlook on the next 5-10 years in the pharmaceutical industry